Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-02-01
2005-02-01
Smith, Lynette R. F. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
06849399
ABSTRACT:
Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4511503 (1985-04-01), Olson et al.
patent: 4666927 (1987-05-01), Hider et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4711845 (1987-12-01), Gelfand et al.
patent: 4912118 (1990-03-01), Hider et al.
patent: 5075469 (1991-12-01), Chevion
patent: 5104865 (1992-04-01), Hider et al.
patent: 5116964 (1992-05-01), Capon
patent: 5185368 (1993-02-01), Peter et al.
patent: 5256676 (1993-10-01), Hider et al.
patent: 5328992 (1994-07-01), Peter et al.
patent: 5385918 (1995-01-01), Connell et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5420008 (1995-05-01), Nishida et al.
patent: 5424057 (1995-06-01), Peter et al.
patent: 5582979 (1996-12-01), Weber
patent: 5705343 (1998-01-01), Drayna et al.
patent: 5712098 (1998-01-01), Tsuchihashi et al.
patent: 5719125 (1998-02-01), Suzuki et al.
patent: 5753438 (1998-05-01), Drayna et al.
patent: 5872237 (1999-02-01), Feder et al.
patent: 6025130 (2000-02-01), Thomas et al.
patent: 6140305 (2000-10-01), Thomas et al.
patent: 6228594 (2001-05-01), Thomas et al.
patent: 6284732 (2001-09-01), Feder et al.
patent: 6391852 (2002-05-01), Feder et al.
patent: 0 315 434 (1989-05-01), None
patent: 0 346 281 (1989-12-01), None
patent: WO 9206180 (1992-04-01), None
patent: WO 9314188 (1993-07-01), None
patent: WO 9315609 (1993-08-01), None
patent: WO 9319768 (1993-10-01), None
patent: WO 9320221 (1993-10-01), None
patent: WO 9401463 (1994-01-01), None
patent: WO 9404186 (1994-03-01), None
patent: WO 9406922 (1994-03-01), None
patent: WO 9406923 (1994-03-01), None
patent: WO 9411367 (1994-05-01), None
patent: WO 9421243 (1994-09-01), None
patent: WO 9508646 (1995-03-01), None
patent: WO 9516663 (1995-06-01), None
patent: WO 9606583 (1996-03-01), None
patent: WO 9617870 (1996-06-01), None
patent: WO 9635802 (1996-11-01), None
patent: WO 9738137 (1997-10-01), None
Alvarez et al. 1990. Biochem. J. 267:31-35.*
Alvarez et al. 1990. J. of Bio. Chem. 266(27): 16644-16655.*
Myers et al. 1985. Science. 230:1242-1246.*
Abravaya, K. et al., “Detection of point mutations with a modified ligase chain reaction (Gap-LCR),”Nucl. Acids Res.23 (4) :675-682 (1995).
Altman, J.D. et al., “Phenotypic analysis of Antigen-Specific T Lymphocytes,”Science274:94-96 (1996).
Anderson, G.J. et al., “Transferrin Receptor Distribution and Regulation in the Rat Small Intestine,”Gastroenterology98:576-585 (1990).
Arteaga, C.L. et al., “Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice,”Canc. Res.56:1098-1103 (1996).
Banerjee, D. et al., “Transferrin Receptors in the Human Gastrointestinal Tract,”Gastroenterology91:861-869 (1986).
Barany, F., “Genetic disease detection and DNA amplification using cloned thermostable ligase,”Proc. Natl. Acad. Sci. U.S.A.88:189-193 (1991).
Bjorkman, P.J. et al., “Structure, Function, and Diversity of Class I Major Histocompatibility Complex Molecules,”Annu. Rev. Biochem.59:253-288 (1990).
Brent, R. et al., “A bacterial repressor protein or a yeast transcriptional terminator can block upstream activation of a yeast gene,”Nature312:612-615 (1984).
Brent, R. et al., “A Eukaryotic Transcriptional Activator Bearing the DNA Specificity of a Prokaryotic Repressor,”Cell43:729-736 (1985).
Carbognani, P. et al., “Transferrin Receptor Expression in Nonsmall Cell Lung Cancer,”Cancer78 (1) :178-179 (1996).
Chien, C-T. et al., The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest,Proc. Natl. Acad. Sci. U.S.A.88:9578-9582 (1991).
Cook, J.D. et al., “Serum Transferrin Receptor,”Annu. Rev. Med.44:63-74 (1993).
Cotton, R.G.H. et al., “Reactivity of Cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations,”Proc. Natl. Acad. Sci. U.S.A.85:4397-4401 (1988).
Cox, G.A. et al., “Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity,”Nature364:725-729 (1993).
Curiel, D.T. et al., “Adenovirus enhancement of transferrin-polylysine-mediated gene delivery,”Proc. Natl. Acad. Sci. U.S.A.88:8850-8854 (1991).
Dadone, M.M. et al., “Hereditary Hemochromatosis. Analysis of Laboratory Expression of the Disease by Genotype in 18 Pedigrees,”Am. J. Clin. Pathol.78 (2) :196-207 (1982).
Dalesandro, J. et al., “Cardiac and Pulmonary Replacement,”J. Thoracic and Cardio. Surgery111(2) :416-422 (1996).
Delahunty, C. et al., “Testing the Feasibility of DNA Typing for Human Identification by PCR and an Oligonucleotide Ligation Assay,”Am. J. Hum. Genet.58:1239-1246 (1996).
Edwards, C.Q. et al., “Prevalence of Hemochromatosis Among 11,065 Presumably Healthy Blood Donors,”N. Engl. J. Med.318 (21) :1355-1362 (1988).
Faham, M. et al., “A Novel In Vivo Method to Detect DNA Sequence Variation,”Genome Res.5:474-482 (1995).
Fahnestock, M.L. et al., “Thermal Stability Comparison of Purified Empty and Peptide-Filled Forms of a class I MHC Molecule,”Science258:1658-1662 (1992).
Fahnestock, M.L. et al., “The MHC Class I Homolog Encoded by Human Cytomegalovirus Binds Endogenous Peptides,”Immunity3:583-590 (1995).
Feder, J.N. et al., “A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis,”Nature Genetics13:399-408 (1996).
Feder, J.N. et al., “The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression,”J. Biol. Chem.272 (22) :14025-14028 (1997).
Fischer, S.G. et al., “DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: Correspondence with melting theory,”Proc. Natl. Acad. Sci. U.S.A.80:1579-1583 (1983).
Friedman, J.M. et al., “Cellular Promoters Incorporated into the Adenovirus Genome: Cell Specificity of Albumin and Immunoglobulin Expression,”Mol. Cell. Biol.6 (11) :3791-3797 (1986).
Gastinel, L.N. et al., “Expression an crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibilty molecules,”Proc. Natl. Acad. Sci. U.S.A.89:638-642 (1992).
Hatzoglou, M. et al., “Hepatic Gene Transfer in Animals Using Retroviruses Containing the Promoter from the Gene for Phosphoenolpyruvate Carboxykinase,”J. Biol. Chem.265 (28) :17285-17293 (1990).
Huber, B.E. et al., “Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy,”Proc. Natl. Acad. Sci. U.S.A.88:8039-8043 (1991).
Jahroudi, N. et al., “Endothelial-Cell-Specific Regulation of von Willebrand Factor Gene Expression,”Mol. Cell. Biol.14 (2) :999-1008 (1994).
Kan, Y.W. et al., “Antenatal Diagnosis of Sickle-Cell Anæmia by D.N.A. Analysis of Anmiotic-Fluid Cells,”Lancetii:910-912 (1978).
Karin, M. et al., “Receptor-mediated Endocytosis of Transferrin in Developmentally Totipotent Mouse Teratocarcinoma Stem Cells,”J. Biol. Chem.256(7) :3245-3252 (1981).
Keer, H.N. et al., “Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo,”J. Urol.143:381-385 (1990).
Klausner, R.D. et al., “Receptor-mediated Endocytosis of Transferrin in K562 Cells,”J. Biol. Chem.258:4715-4724 (1983).
Koç, O.N. et al., “Transfer of Drug Resistance Genes into Hemotopoietic Progenitors to Improve Chemotherapy Tolerance,”Sem. Oncol.23 (1) :46-65 (1996).
Landegren, U. et al., “A Ligas
Feder John N.
Schatzman Randall C.
Tsuchihashi Zenta
Bio-Rad Laboratories, Inc.
Hines Ja'Na
Jones Day
Smith Lynette R. F.
LandOfFree
Methods and compositions for diagnosis and treatment of iron... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosis and treatment of iron..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosis and treatment of iron... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486722